The estimated Net Worth of Renee Lentini is at least $3.9 Million dollars as of 2 February 2024. Ms Lentini owns over 8,435 units of Immunogen stock worth over $542,139 and over the last 4 years she sold IMGN stock worth over $3,356,843.
Ms has made over 5 trades of the Immunogen stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 8,435 units of IMGN stock worth $263,509 on 2 February 2024.
The largest trade she's ever made was selling 219,545 units of Immunogen stock on 6 November 2023 worth over $3,356,843. On average, Ms trades about 25,968 units every 10 days since 2021. As of 2 February 2024 she still owns at least 17,354 units of Immunogen stock.
You can see the complete history of Ms Lentini stock trades at the bottom of the page.
Renee Lentini is the VP of Fin., Principal Accounting Officer & Corp. Controller at Immunogen.
Ms Lentini is 43, she's been the VP of Fin. and Principal Accounting Officer & Corp. Controller of Immunogen since . There are 15 older and 1 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
Renee's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: